SGLT2 Inhibitor Prescribing in Cardiovascular-Kidney-Metabolic Syndrome

Am J Cardiovasc Drugs. 2024 Nov;24(6):841-844. doi: 10.1007/s40256-024-00687-9. Epub 2024 Oct 9.

Brandon D Beers¹, Bhavya Chebrolu¹, Gretchen M Stern¹, Leo F Buckley¹, Muthiah Vaduganathan^{2

3}, Deepak L Bhatt⁴, Thomas D Bernier^{5

6}

¹ Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.
² Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
³ Harvard Medical School, Boston, MA, USA.
⁴ Icahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA.
⁵ Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA. thomas_bernier@rush.edu.
⁶ Department of Pharmacy, Rush University Medical Center, 1620 W Harrison Street, Chicago, IL, 60612, USA. thomas_bernier@rush.edu.

No abstract available

Keywords: Cardiometabolic; Prescribing; Sodium-glucose cotransporter-2 inhibitors.

Publication types